Dr. Al-Kali on FDA Approval of Inotuzumab Ozagamicin in ALL

August 17, 2017

Aref Al-Kali, MD

In Partnership With:

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).